Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
13Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Damora Therapeutics, Inc. (GLTO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
17Total relationships
1Distinct source URLs
4High confidence
0.745Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Damora Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
PARAGON
PARAGON
90%
the Company is obligated to compensate Paragon for its services performed under each research program based on the actual costs incurred with mark-up costs pursuant to the terms of the Paragon Option…
Reciprocal relationship from IRON graph: Reciprocal relationship from GLTO graph: 026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable futur…
026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter …
Reciprocal relationship from KPTI graph: Reciprocal relationship from GLTO graph: Reciprocal relationship from KPTI graph: Reciprocal relationship from GLTO graph: 026, we had an accumulated deficit …
026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter …
Reciprocal relationship from MRK graph: Reciprocal relationship from GLTO graph: 026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable future…
026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter …
Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLTO graph: 026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable futu…
026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter …
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from GLTO graph: operty litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be co…
SNYNF
Sanofi
72%
operty litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. Further, we may be required to protect our future patents, if …
HONG-KONG-LIMITED
HONG-KONG-LIMITED
62%
ds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market. Risks associated with th…
INCA035784-JANSSEN-PHARMACEUTICALS-INC
INCA035784-JANSSEN-PHARMACEUTICALS-INC
62%
026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter …
Reciprocal relationship from JNJ graph: Reciprocal relationship from GLTO graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GLTO graph: 026, we had an accumulated deficit of…
Damora Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
GLTO-DEBT-9806
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
GLTO-DEBT
Debt stack $72,000
90%
Market cache reports total debt of $72,000.
Damora Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Damora Therapeutics, Inc..
Damora Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
GLTO-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 67 tracked holders.
Damora Therapeutics, Inc. Extended Supply Chain Network
